was approved by U.S. Food and Drug Administration (FDA) in May 2003. Since then it has been linked with many side effects. Boniva is the brand name for ibandronate. It belongs to the bisphosphonates group of medicines. It is used for treatment of osteoporosis in women after menopause. It also prevents osteoporosis by affecting the bone formation and breakdown cycle. It slows down the process of bone loss and can even increase bone mass. This alteration prevents bone fractures. Though it is mainly used to treat osteoporosis, it is also used for other purposes as well. The chemical name of ibandronate sodium is 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1, 1diphosphonic acid. It is monosodium salt, monohydrate and its formula is C9H22NO7P2Na•H2O.

From time to time, the FDA has issued different warnings and instructions to alert consumers and physicians of the adverse effects of this drug. The FDA issued a notice regarding label changes of Boniva in November 2008. These changes were approved by the FDA Center for Drug Evaluation and Research (CDER). These new warning labels included adverse reactions in the upper gastrointestinal area, hypocalcemia, mineral metabolism and musculoskeletal pain. The label also warned of adverse effects of Boniva such as ocular adverse events and acute phase reaction.

Previous ArticleHow to file a Boniva lawsuit Next ArticlePaxil: Medical Use and Drug Facts
Verdicts and Settlements
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers